AI treatment is standard of care for breast cancer (BC), yet BC cells frequently display drug-resistance and stronger metastatic potential at relapse, suggesting that chronic exposure to endocrine treatment might contribute in shaping the invasive potential, as suggested by previous in vitro studies 5 . The mechanism/s, order of events and molecular players mediating these phenomena are not well understood but it is likely that they involve cytoskeletal re-arrangements as they are essential for cancer invasion and metastasis 6 . One possibility is that endocrine therapies (ET) might indirectly promote invasive potential by selecting for interrelated phenotypes during tumor evolution 7-9 . Alternatively, AI treatment may directly contribute to the activation of invasive transcriptional programs. Chronic exposure to ET leads to coordinated activation and decommissioning of regulatory regions such as enhancer and promoters as shown by global changes in the localization of epigenetic marks Figure 1A and S1A-B). Measuring KRT80 transcripts before or after shortterm (48hrs) acute estrogen starvation using single cell RNA-seq data we showed that the significant increase in KRT80 positive cells is driven by transcriptional activation
H3K27ac and H3K4me1-2 5,9,10 . These epigenetic changes occasionally involve entire topological associating domains (TADs), three-dimensional compartments within the genome thought to restrict enhancer-promoter interactions 3, 11 . We observed that the type II keratin TAD ranked among the most significantly epigenetically reprogrammed (top 5%) when comparing untreated, non-invasive parental vs. invasive AI resistant BC cell lines 5 (long term estrogen deprived: LTED cells, Figure 1A ). Type I and Type II Keratins are the main constituents of cytoplasmic intermediate filaments and are involved in crucial cellular processes including cell attachment, stress adaptation and cell structure maintenance; yet very little is known about their role in cell movement and metastatic progression. Despite TAD dynamics, only few keratins within the type II-keratin TAD were transcriptionally reprogrammed in AI-resistant cell lines, including KRT80 ( Figure 1A and S1A-B). Measuring KRT80 transcripts before or after shortterm (48hrs) acute estrogen starvation using single cell RNA-seq data we showed that the significant increase in KRT80 positive cells is driven by transcriptional activation
and not selection of KRT80-positive clones ( Figure 1B) . These data were validated in MCF7 and LTED cells using single cell RNA-FISH ( Figure 1C ). As expected, increased transcription corresponded to increased KRT80 protein level ( Figure 1D ).
KRT80 is a largely unknown keratin structurally related to hair keratins 12 , in contrast with epithelial keratins commonly found in normal epithelial cells. This led us to further explore the role of KRT80 in promoting the aberrant phenotype observed in AIresistant cells. KRT80 transcripts were also elevated in several ERα-negative cell lines, suggesting that upregulation in drug-resistant cells was not mediated by changes in ERα activity (Table S1 ). More importantly, IHC analysis of two independent clinical datasets confirmed that KRT80 positive cells increase after AI treatment but not Tamoxifen in vivo 13,14 ( Figure 1E ). KRT80 localization in vivo was radically different to what has been shown in conventional keratins (e.g. KRT8, KRT14, KRT18 or KRT19 15 ), presenting a peri-nuclear polarized pattern towards the lumen within healthy ducts and lobules ( Figure 1F and S2). Similar staining patterns were conserved in benign lesions ( Figure S2 ), whereas KRT80 staining became strongly cytoplasmic in higher grade BC and metastatic lesions suggesting a potential role in BC progression ( Figure 1E ). Correspondingly, high KRT80 mRNA levels correlated with poor survival in the TCGA-BC dataset (Fig. 1G) . These data were confirmed by multivariate metaanalysis of two independent datasets with additional clinical endpoints ( Figure S3 ).
Activation of cell type specific enhancers has been linked with cancer transcriptional aberration 9,16-18 , leading us to hypothesize that de novo enhancer activation within the TAD structure might control KRT80 expression in AI resistant cells. We used H3K27ac, an epigenetic mark associated with gene activation 9, 19 , to identify KRT80 potential enhancers (E1 and E2, Figure S4A ). As expected, E1-E2 activity was only captured in KRT80-positive cells ( Figure S4A ). 3D meta-analysis from parental MCF7 ChIA-Pet data strongly suggested that the E1 loci could contact the KRT80 promoter via enhancer-promoter interactions, while it excluded the weaker E2 ( Figure S4B ) suggesting that the 3D interaction is already pre-establihed in sensitive cells. To test whether E1 drove KRT80 transcriptional activity we adapted Figure. 2C and S6C) .
Interestingly, the expression of KRT80 and SREBP1 target genes was also strongly correlated in BC patients ( Figure. S6D) . Finally, we show that SREBP1 silencing abrogated KRT80 expression in LTED cells ( Figure. 2D) . Overall these data demonstrate an unpredicted link between SREBP1 and KRT80 activation. Intriguingly, the footprint containing the SREBP1 motif was not under significant evolutionary constraint ( Figure. S7) (Figure 1-2) . In agreement, we observed a significant increase in cellular stiffness (inversely correlated to cell compliance) after KRT80 over-expression in MCF7 and LTED cells ( Figure 2E ). To test if KRT80 can contribute to tumor stiffness in vivo we prospectively recruited 20 patients with suspected BC and performed shearwave elastography to measure intra-tumoral stiffness ( Figure 2F ). Our data showed that cancer lesions had significantly higher stiffness than surrounding normal tissues, with the highest peak of stiffness consistently measured at the invasive border ( Figure   2F ). Interestingly, meta-analysis of tumor and matched nearby tissue from TCGA show increased KRT80 mRNA in the tumor biopsies ( Figure 2F ). We then performed IHC for KRT80 with validated antibodies (Figure 2G and S8) using biopsies collected from our prospective patients. Linear regression analysis showed that KRT80 positivity significantly correlated with intra-tumor stiffness ( Figure 2G and S8) . Collectively, these data demonstrate that BCs characterized with high KRT80 content are mechanically stiffer.
The effect of increasing stiffness in metastatic invasion is highly debated. 
Online Materials and Methods

Cell lines and cell culture
In this study we used MCF7 breast adenocarcinoma cell line and derived resistant clones (Supplementary Figure 1) . MCF7 Tamoxifen 
Library preparation
Prior to sequencing, ChIP samples were library prepared using the NEBNext Ultra II 
3D Organoid assay
250,000 cells were resuspended in 1 mL of the corresponding media and 20 μL drops were placed in the lid of a 10 cm dish (Corning). The lid was flipped over the dish containing 5 mL of media in order to prevent evaporation. Hanging drops were incubated for 5 days at 37% C in a humidified atmosphere, during which formation of organoids was achieved. To follow, organoids were immersed in 10 μL of phenol-red free Matrigel® (BD Biosciences) and placed in a 24 well-plate (Corning) The appropriate media containing G418 or puromycin was subsequently added to the well.
Brightfield images were acquired at days zero and day two using an EVOS microscope (Advanced Microscopy Group, Life Technologies). Images were analysed using Fiji
ImageJ software and fold-change area was calculated using the following formula:
Area (fold-change) = Area Day 2/Area Day 0
Immunofluorescence and confocal microscopy
Organoids were washed with PBS and fixed for 15 minutes with 4 % PFA/PBS. 
Tissue specimens
Seventy-five human breast specimens and ten metastatic lymph nodes were selected from Histopathology Department at Charing Cross Hospital, with the previous approval of Imperial College Healthcare NHS Trust Tissue Bank.
A Tissue Microarray (TMA) containing 26 primary breast tumors and paired ETR relapses was constructed as previously described (18).
Immunohistochemistry staining was scored using a quick score system by two independent investigators, one of them a consultant pathologist (SS). Score was calculated as follows: S=3 (strongly stained cells), S=2 (moderate staining), S=1
(poorly stained cells) and S=0 (absence of staining). Staining intensity was assessed as mean intensity from the tumor region contained within the TMA.
Immunohistochemistry
Formalin fixed and paraffin embedded (FFPE) tissue specimens were sliced in 4 µm sections using a Leica RM2235 manual microtome. Dried sections were de-waxed by immersion in xylene and rehydrated with subsequent immersion in 100% ethanol, 70 % ethanol and distilled water. 
Statistical analysis
Data is presented as mean ± SD (standard deviation). Data analysis was performed using GraphPad Prism 6 software. An unpaired two-tailed Student's t test was applied to all data, except from a non-parametric Mann-Whitney test applied to TMA score.
Survival analysis
Publicly available breast cancer datasets were identified in GEO (https://www.ncbi.nlm.nih.gov/geo/), EGA (https://www.ebi.ac.uk/ega/home), and TCGA (https://cancergenome.nih.gov/). Only cohorts including at least 30 patients and with available follow-up data were included. Samples derived using different technological platforms (Affymetrix gene chips, Illumina gene chips, RNA-seq) were processed independently. For KRT80, the probe set 231849_at was used in the Affymetrix dataset, the probe ILMN_1705814 was used in the Illumina dataset and the gene 144501 was used in the RNA-seq dataset. Cox proportional hazards survival analysis was performed as described previously 35 . Kaplan-Meier plots were derived to visualize survival differences. In the multivariate analysis, the RNA expression of ERα, HER2, and MKI67 were used as surrogate markers for ER and HER2 status, and for proliferation. In this, the probe sets 205225_at, 216836_s_at, and 212021_s_at were used for ERα, HER2, and MKI67, respectively. The survival analysis was performed for relapse-free survival (RFS), overall survival (OS), and post-progression survival (PPS). PPS was computed by extracting the RFS time from the OS time for patients having both RFS and OS data and having an event for RFS. Censoring data for PPS was derived from the OS event. The survival analysis was performed in the R statistical environment.
Cellular microrheology
To characterize the mechanical properties of the four different BC cell lines, we used magnetic tweezer microrheology to measure cell deformation in response to magnetically generated forces. Tensional magnetic forces were induced by a high was set to 1 sec. The creep compliance J(t) represents the ratio ( γ(t)/σ0 ) of the localized cellular strain γ(t) induced by the applied stress from the magnetic tweezers σ0, with γ(t) taken as the radial bead displacement normalised over the bead radius γ(t)=d(t)/r and the applied stress as σ0 =F0/4πr 2 taken as the applied force normalised over the bead cross sectional area. Compliance measurements for each BC cell line were collected from three independent experiments (MCF7 CTRL n=60, MCF7 KRT80 n=34, LTED CTRL n=41, LTED KRT80 n=34).
Shearwave Elastography
All SWE was performed by a breast radiologist with more than 10-years experience of performing Breast ultrasound and elastography on breast lesions. A state-of-the art ultrasound scanner, Aplio i900 (Canon Medical Systems, Nasu, Japan) with the latest 2D SWE technology was used for this study. All SWE maps and calculations were obtained pre-biopsy. A good stand-off was used for superficial lesions and initially, continuous SWE mode ("multi-shot") was used to select the optimum plane and once this was stabilised, a higher energy SWE push-pulse ("one-shot" mode) was then utilised to obtain the final elastogram for calculations. Regions of interest (ROI) were placed within the centre of the lesion, in the periphery and also within the adjacent normal breast tissue. This has been stored as raw data within the ultrasound systems which would enable any re-calculations as necessary. Manipulation of KRT80 directly reprogram these sub-structures. 
